Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05150184
Other study ID # NH10009
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 17, 2021
Est. completion date May 23, 2023

Study information

Verified date September 2023
Source Danisco
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Isolation and characterization of fecal/oral/skin/nasal/throat microbial species from a diverse cohort of healthy adults.


Description:

This study aims at isolation and characterizing microbial species from the diverse cohort for future development as next generation probiotics and includes the characterization of the human fecal/oral/skin/nasal and throat microbiome.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date May 23, 2023
Est. primary completion date March 23, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Voluntary, written, informed consent to participate in the study 2. Agreement to comply with the protocol and study restrictions 3. Healthy females and males of age 18 to 50 years (inclusive) 4. Participants recognize themselves as white or American Indian or Alaska Native or Asian or Black / African American or Native Hawaiian or Other Pacific Islander or Hispanic and Latinos or Multiracial. Participant numbers are limited to a maximum of 10 (males and females) from each group. 5. Participants consume > 4 portions of fruits and vegetables per day and who agree to maintain their usual dietary habits, their usual exercise habits, hygienic habits and their lifestyle in general throughout the trial period 6. Females of child-bearing potential who agree to use medically approved methods of birth control 7. Ability of the participant (in the investigator's opinion) to comprehend the full nature and purpose of the study 8. BMI between 18.5-25. Exclusion Criteria: 1. Participation in a clinical trial with an investigational product or drug within 60 days prior to screening. 2. Likeliness to be noncompliant with the protocol, or to be unsuitable to the study as judged by the study staff for any reason. 3. Planned major changes in life style (i.e. diet, dieting, exercise level, travelling). 4. History of diagnosed eating disorder (anorexia, bulimia). 5. Consumption of fast food > 3 times/week. Where fast food is referred to high carbohydrate and fat rich diet. 6. History of drug (> 2 times per week) during last 2 years or alcohol abuse (> 08 portions per week for females and 15 portions/week for males, or >3 portions/day) during the last 3 months. 7. Pregnant or breastfeeding women; women planning to become pregnant during the study. 8. Clinically significant underlying systemic illness that may preclude the participant's ability to complete the trial or that may affect the study outcomes (e.g. bowel cancer, prostate cancer, terminal illness, coronary heart disease/cardiovascular disease or artificial heart valve, HIV, STD, AIDS, hepatitis and autoimmune diseases e.g. MS-disease, thyroid diseases) 9. Use of prescription anti-obesity drugs, temporary or irregular medication for diabetes, dyslipidemia or hypertension, non-steroidal anti-inflammatory drugs, corticosteroids, or equivalent immunomodulatory drugs, immunosuppression or ongoing therapy causing immunosuppression and ongoing or recent (last 3 months) antibiotic treatment. 10. Diagnosed or suspected organic gastrointestinal disease (e.g. colitis, Crohn's disease, celiac disease, recurrent diverticulitis) or non-organic disease (e.g. IBS), or functional constipation, during the last year. 11. Colonoscopy within 3 months before screening 12. Colon cleansing within 3 months before screening. 13. Gastrointestinal infection within 6 months before screening 14. Active or recent (last 3 months) participation in a weight loss program including weight change (increase or loss) of 3 kg during the past three months. History of bariatric surgery. 15. History of gingivitis, periodontitis, or any oral disease during last 6 months. 16. History of smoking or tobacco use in any form and/or electronic cigarette during the last 6 months. 17. History of skin diseases (e.g. atopic dermatitis (Eczema), hives, dermatitis, psoriasis, or rashes) during the last 6 months. 18. History of SARS CoV-2 infection. 19. Participants under administrative or legal supervision. 20. Other reasons that, in the opinion of the Investigator, make the participant unsuitable for enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Non-interventional
observational study, thus no different arm/groups

Locations

Country Name City State
United States Reprocell Beltsville Maryland

Sponsors (3)

Lead Sponsor Collaborator
Danisco Reprocell Inc, Serologix

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analysis of microbiomes from various body sites Analysis of microbiomes from various body sites within 2 weeks of collection
See also
  Status Clinical Trial Phase
Recruiting NCT05560087 - Association of PeRiODontal Disease and gUt Microbiome With Coronary artEry Disease (PRODUCE Study)
Completed NCT04222699 - Cultures Before and After Decolonization in Community Dwelling Adults With Current S. Aureus Colonization Phase 4
Completed NCT02392182 - Lung HIV Microbiome Project (Michigan Site) N/A
Completed NCT04597502 - The Effects of Terminalia Chebula Fruit Extract on the Gut Microbiome and Skin Biophysical Properties N/A
Completed NCT04596722 - Oral Pomegranate Extract on the Microbiome and Skin Biophysical Properties N/A
Completed NCT02731976 - Microbiome Composition Changes on 4 Week Gluten-free Diet Challenge N/A
Recruiting NCT03942159 - Modification of the Human Colon and Oral Microbiome by Allogenic HSCT
Completed NCT04335526 - A Clinical Study to Assess the Effect of Change of Bile Acid on the PD and Safety of Metformin and Microbiome Profiles Phase 1
Completed NCT03668015 - Xylitol and Sorbitol Effects on the Oral Microbiome N/A
Completed NCT03157687 - Detection of Luminal and Mucosa-associated Microbiome in Healthy Controls vs. Local and Systemic Inflammation
Not yet recruiting NCT04841694 - Oral Probiotics on the Shift in Gut Microbiome and Skin Carotenoid Levels N/A
Enrolling by invitation NCT03231332 - Effects of H.Pylori Eradication on Microbiome Phase 4
Completed NCT03181269 - Human Milk and Infant Intestinal Microbiome Study N/A
Completed NCT03543605 - Clinical/Microbiological Impact of a Specific Antimicrobial Stewardship Program for Nursing Homes N/A
Completed NCT01496898 - Changes in Vaginal, Cervical and Uterine Microflora With Levonorgestrel Intrauterine Device Placement N/A
Terminated NCT03907501 - Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation N/A
Completed NCT03809260 - A Clinical Trial for Analysis of Intestinal Microbiome Affecting PK, PD, and Safety of Metformin N/A
Completed NCT04218799 - Human Microbiome and Healthcare Associated Infections - Nursing Home Dwelling Older Veterans Phase 4
Completed NCT03581812 - Snack Foods and Their Impact on Gastrointestinal Microbiology, Function and Symptoms N/A
Withdrawn NCT02407184 - Potential Restoration of the Infant Microbiome N/A